44.15
+0(+0.00%)
Currency In USD
Address
10 Post Office Square
Boston, MA 02109
United States of America
Phone
857 254 5555
Sector
Healthcare
Industry
Biotechnology
Employees
130
First IPO Date
May 11, 2007
| Name | Title | Pay | Year Born |
| Mr. Ronald H. W. Cooper | Chief Executive Officer, Pres & Director | 1.1M | 1963 |
| Mr. Simon Nicolas Reade Harford | Chief Financial Officer & Treasurer | 687,784 | 1961 |
| Ms. Martha J. Carter | Chief Regulatory Officer | 710,689 | 1952 |
| Ms. Pamela Stephenson M.P.H. | Chief Commercial Officer | 0 | 1968 |
| Dr. Per-Goran Gillberg Ph.D. | Co-Founder & Vice President of Devel. | 0 | N/A |
| Ms. Joan Connolly | Chief Technology Officer | 0 | N/A |
| Dr. Jan P. Mattsson Ph.D. | Chief Scientific Officer, MD (Sweden) & Co-Founder | 0 | 1964 |
| Mr. Jason G. Duncan | Chief Legal Officer, Gen. Counsel & Sec. | 0 | 1974 |
| Ms. Michelle Graham | Chief HR Officer | 0 | 1967 |
| Dr. Kristina Torfgard | Vice President & Global Project Head | 0 | N/A |
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia, alagille syndrome, and rare and life-threatening disorder to children; and Elobixibat for the treatment of chronic constipation and other functional diseases. It also engages in the developing of A3907, which is in Phase I clinical trial for the treatment of adult liver diseases; and A2342, a preclinical candidate to treat adult viral and liver diseases. The company has a license agreement with EA Pharma Co., Ltd. for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.